In light of the considerable therapeutic prospects offered by immunotherapy, particularly with regard to PD-1 and PD-L1 immune checkpoint inhibitors, in various types of malignancies, including BLCA, we undertook a thorough assessment to determine the prognostic implications of the risk score within the IMvigor210 and GSE78220 cohorts. The gene discussed is CD274; the disease is bladder transitional cell carcinoma.